saxagliptin pharos 2.5 mg film-coated tablets
pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - film-coated tablet - saxagliptin 2.5 mg - drugs used in diabetes
saxagliptin pharos 5 mg film-coated tablets
pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - film-coated tablet - saxagliptin 5 mg - drugs used in diabetes
qtern tablet
astrazeneca canada inc - saxagliptin (saxagliptin hydrochloride); dapagliflozin (dapagliflozin propanediol monohydrate) - tablet - 5mg; 5mg - saxagliptin (saxagliptin hydrochloride) 5mg; dapagliflozin (dapagliflozin propanediol monohydrate) 5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors
qtern tablet
astrazeneca canada inc - saxagliptin (saxagliptin hydrochloride); dapagliflozin (dapagliflozin propanediol monohydrate) - tablet - 5mg; 10mg - saxagliptin (saxagliptin hydrochloride) 5mg; dapagliflozin (dapagliflozin propanediol monohydrate) 10mg - dipeptidyl peptidase-4 (dpp-4) inhibitors
onglyza tablet
astrazeneca canada inc - saxagliptin (saxagliptin hydrochloride) - tablet - 5mg - saxagliptin (saxagliptin hydrochloride) 5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors
onglyza tablet
astrazeneca canada inc - saxagliptin (saxagliptin hydrochloride) - tablet - 2.5mg - saxagliptin (saxagliptin hydrochloride) 2.5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors
onglyza 2.5
astrazeneca pharmaceutical (pty) ltd - saxagliptin hydrochloride - tablets - each tablet contains saxagliptin hydrochloride equivalent to saxagliptin base 2,5 mg
onglyza 5
astrazeneca pharmaceutical (pty) ltd - saxagliptin hydrochloride - tablets - each tablet contains saxagliptin hydrochloride equivalent to saxagliptin base 5 mg
qtern
astra zeneca ab - saxagliptin, dapagliflozin propanediol monohydrate - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - drugs used in diabetes - qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of qtern do not provide adequate glycaemic control,when already being treated with the free combination of dapagliflozin and saxagliptin.(see sections 4.2, 4.4, 4.5 and 5.1 for available data on combinations studied.)
onglyza 5mg tablets
astrazeneca uk ltd - saxagliptin hydrochloride - tablet - 5mg